5/1/2014 3:01:39 PM
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the quarter March 31, 2014.
Exact reported total revenues of $0.3 million for the first quarter of 2014, compared to $1.0 million for the first quarter of 2013. Our revenue has been comprised of the non-cash amortization of up-front license fee payments paid to us by Genzyme Corp., which was amortized over a five-year collaboration period ending in January 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by